PXL/HO/BEC-005/2021-22 Dt: 26.04.2021
Dear Sir/Madam,
Subject: Supply Offer for Remdessa (remdesivir) by JV Jurabek Laboratories, Uzbekistan
We are glad to inform our member companies that Pharmexcil is in receipt of Communication from Embassy of Uzbekistan in New Delhi wherein a leading Pharmaceutical company from Uzbekistan “JV Jurabek Laboratories” has offered to supply Remdessa (remdesivir), a lyophilisate for the preparation of an infusion solution to India.
M/s.JV Jurabek Laboratories is a leading Pharmaceutical Company in Uzbekistan producing infusion, injection, tablets, capsule, antibiotics, and lyophilized products and has registration of products in countries such as Georgia, Azerbaijan, Kirgiz Republic, Tajikistan, Afghanistan, Moldova and others.
Considering the prevailing shortage of the drug in India, interested member companies may like to review and consider the offer by JV Jurabek Laboratories. The details of available stock and expected price as intimated are as below for your ready reference: Please find attached the offer received from JV Jurabek Laboratories
Available stock : 170 000 vials No1 box
Price CIP INDIA : 30 USD per box Delivery
Terms : DHL or by air
Interested member companies are requested to approach the Nodal person of the M/s.JV Jurabek Laboratories directly with a copy to Uzbekistan embassy in New Delhi: i.salimov@mfa.uz.
Nodal person of JV Jurabek Laboratories
Karieva M.D,General Director
email id: info@jurabek.uz
Local Representative in India:
Dr. Basava Bhaaskara
Roerich Healthcare Pvt Ltd,
email id: bhaaskara@roerich.in or bhaaskara@gmail.com
Ph.NO: +91 8008002997
With regards
Uday Bhaskar
Director General
Important Note: Members may please note that the above information is circulated on the basis of information received from Embassy of Uzbekistan, New Delhi. Members are advised to make their own decisions before finalizing their business transactions.
|
